- Home
- LDI vs YMAB Comparison
LDI vs YMAB Comparison
Compare LDI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- YMAB
- Stock Information
- Founded
- LDI 2010
- YMAB 2015
- Country
- LDI United States
- YMAB United States
- Employees
- LDI N/A
- YMAB N/A
- Industry
- LDI Finance: Consumer Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- LDI Finance
- YMAB Health Care
- Exchange
- LDI Nasdaq
- YMAB Nasdaq
- Market Cap
- LDI 221.2M
- YMAB 192.4M
- IPO Year
- LDI 2021
- YMAB 2018
- Fundamental
- Price
- LDI $1.31
- YMAB $4.60
- Analyst Decision
- LDI Sell
- YMAB Buy
- Analyst Count
- LDI 3
- YMAB 11
- Target Price
- LDI $1.98
- YMAB $17.55
- AVG Volume (30 Days)
- LDI 735.5K
- YMAB 226.0K
- Earning Date
- LDI 05-06-2025
- YMAB 05-13-2025
- Dividend Yield
- LDI N/A
- YMAB N/A
- EPS Growth
- LDI N/A
- YMAB N/A
- EPS
- LDI N/A
- YMAB N/A
- Revenue
- LDI $1,090,719,000.00
- YMAB $88,658,000.00
- Revenue This Year
- LDI $28.75
- YMAB N/A
- Revenue Next Year
- LDI $15.05
- YMAB $16.03
- P/E Ratio
- LDI N/A
- YMAB N/A
- Revenue Growth
- LDI 21.07
- YMAB 4.92
- 52 Week Low
- LDI $1.01
- YMAB $3.55
- 52 Week High
- LDI $3.23
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- LDI 60.49
- YMAB 56.43
- Support Level
- LDI $1.18
- YMAB $3.99
- Resistance Level
- LDI $1.36
- YMAB $5.00
- Average True Range (ATR)
- LDI 0.08
- YMAB 0.35
- MACD
- LDI 0.02
- YMAB 0.10
- Stochastic Oscillator
- LDI 81.48
- YMAB 70.47
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.